Bulgaria - Sofia: Pharmaceutical products

ID

ocds-pyfy63:2020-255944:2020-376838

Buyer

„Spetsializirana bolnitsa za aktivno lechenie na onkologichni zabolyavaniya — Sofiya-oblast“ EOOD

Date

2020-08-11

Language

BG

Tags

award

Release in JSON

ID (OCID)

ocds-pyfy63:2020-255944

Releases

2020-06-03 (ocds-pyfy63:2020-255944:2020-255944)
2020-08-11 (ocds-pyfy63:2020-255944:2020-376838)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601521)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601522)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601525)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601558)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601559)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601563)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601579)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601580)
2020-12-14 (ocds-pyfy63:2020-255944:2020-601610)

Releases in JSON

Title

Bulgaria - Sofia: Pharmaceutical products

Award criteria

priceOnly

Award criteria details

Lowest price

Award criteria for item 1:
- Price

Award criteria for item 2:
- Price

Award criteria for item 3:
- Price

Award criteria for item 4:
- Price

Award criteria for item 5:
- Price

Award criteria for item 6:
- Price

Award criteria for item 7:
- Price

Award criteria for item 8:
- Price

Award criteria for item 9:
- Price

Award criteria for item 10:
- Price

Award criteria for item 11:
- Price

Award criteria for item 12:
- Price

Award criteria for item 13:
- Price

Award criteria for item 14:
- Price

Award criteria for item 15:
- Price

Award criteria for item 16:
- Price

Award criteria for item 17:
- Price

Award criteria for item 18:
- Price

Award criteria for item 19:
- Price

Award criteria for item 20:
- Price

Award criteria for item 21:
- Price

Award criteria for item 22:
- Price

Award criteria for item 23:
- Price

Award criteria for item 24:
- Price

Award criteria for item 25:
- Price

Award criteria for item 26:
- Price

Award criteria for item 27:
- Price

Award criteria for item 28:
- Price

Award criteria for item 29:
- Price

Award criteria for item 30:
- Price

Award criteria for item 31:
- Price

Award criteria for item 32:
- Price

Award criteria for item 33:
- Price

Award criteria for item 34:
- Price

Award criteria for item 35:
- Price

Award criteria for item 36:
- Price

Award criteria for item 37:
- Price

Award criteria for item 38:
- Price

Award criteria for item 39:
- Price

Award criteria for item 40:
- Price

Award criteria for item 41:
- Price

Award criteria for item 42:
- Price

Award criteria for item 43:
- Price

Award criteria for item 44:
- Price

Award criteria for item 45:
- Price

Award criteria for item 46:
- Price

Award criteria for item 47:
- Price

Award criteria for item 48:
- Price

Award criteria for item 49:
- Price

Award criteria for item 50:
- Price

Award criteria for item 51:
- Price

Award criteria for item 52:
- Price

Award criteria for item 53:
- Price

Award criteria for item 54:
- Price

Award criteria for item 55:
- Price

Award criteria for item 56:
- Price

Award criteria for item 57:
- Price

Award criteria for item 58:
- Price

Award criteria for item 59:
- Price

Award criteria for item 60:
- Price

Award criteria for item 61:
- Price

Award criteria for item 62:
- Price

Award criteria for item 63:
- Price

Award criteria for item 64:
- Price

Award criteria for item 65:
- Price

Award criteria for item 66:
- Price

Award criteria for item 67:
- Price

Award criteria for item 68:
- Price

Award criteria for item 69:
- Price

Award criteria for item 70:
- Price

Award criteria for item 71:
- Price

Award criteria for item 72:
- Price

Award criteria for item 73:
- Price

Award criteria for item 74:
- Price

Award criteria for item 75:
- Price

Award criteria for item 76:
- Price

Award criteria for item 77:
- Price

Award criteria for item 78:
- Price

Award criteria for item 79:
- Price

Award criteria for item 80:
- Price

Award criteria for item 81:
- Price

Award criteria for item 82:
- Price

Award criteria for item 83:
- Price

Award criteria for item 84:
- Price

Award criteria for item 85:
- Price

Main procurement category

goods

Procurement method

open

Procurement method details

Open procedure

Tender period

2020-08-11 - ?

ID

ocds-pyfy63:2020-255944:obj:1

Classification

CPV / 33600000

Description

Mycobacterium bovis BCG (Baccilus Calmette — Guerin), парентерална форма, прогнозно количество — 18 720 mg.

ID

ocds-pyfy63:2020-255944:obj:2

Classification

CPV / 33600000

Description

Erythropoietin (Epoetin alfa) 10 000 IU/1ml., парентерална форма, прогнозно количество 300 000 IU.

ID

ocds-pyfy63:2020-255944:obj:3

Classification

CPV / 33600000

Description

Darbepoetin alfa 300 mcg., парентерална форма, прогнозно количество 30 000 mcg.

ID

ocds-pyfy63:2020-255944:obj:4

Classification

CPV / 33600000

Description

Octreotide 30 mg., парентерална форма, прогнозно количество 2 160 mg.

ID

ocds-pyfy63:2020-255944:obj:5

Classification

CPV / 33600000

Description

Octreotide 20 mg., парентерална форма, прогнозно количество 1 000 mg.

ID

ocds-pyfy63:2020-255944:obj:6

Classification

CPV / 33600000

Description

Cyclophosphamide 500 mg., парентерална форма, прогнозно количество 190 000 mg.

ID

ocds-pyfy63:2020-255944:obj:7

Classification

CPV / 33600000

Description

Temozolomide 100 mg., Capsule, hard, перорална форма, прогнозно количество 55 000 mg.

ID

ocds-pyfy63:2020-255944:obj:8

Classification

CPV / 33600000

Description

Pemetrexed 25 mg/ml - 20 ml, парентерална форма, прогнозно количество 30 000 mg.

ID

ocds-pyfy63:2020-255944:obj:9

Classification

CPV / 33600000

Description

Fluorouracil 50mg/ml – 20 ml., парентерална форма, прогнозно количество 1 930 000 mg.

ID

ocds-pyfy63:2020-255944:obj:10

Classification

CPV / 33600000

Description

Gemcitabine 1000 mg., парентерална форма 800 000 mg.

ID

ocds-pyfy63:2020-255944:obj:11

Classification

CPV / 33600000

Description

Capecitabine 500 mg., перорална форма, film coated tablet, прогнозно количество 7 320 000 mg.

ID

ocds-pyfy63:2020-255944:obj:12

Classification

CPV / 33600000

Description

Vinorelbine 10 mg/ml - 5 ml, парентерална форма, прогнозно количество 5 000 mg.

ID

ocds-pyfy63:2020-255944:obj:13

Classification

CPV / 33600000

Description

Etoposide 20 mg/ml- 5 ml., парентерална форма, прогнозно количество 120 000 mg.

ID

ocds-pyfy63:2020-255944:obj:14

Classification

CPV / 33600000

Description

Paclitaxel 100 mg., парентерална форма, прогнозно количество 72 800 mg.

ID

ocds-pyfy63:2020-255944:obj:15

Classification

CPV / 33600000

Description

Paclitaxel 300 mg., парентерална форма, прогнозно количество 33 000 mg.

ID

ocds-pyfy63:2020-255944:obj:16

Classification

CPV / 33600000

Description

Docetaxel 160 mg., парентерална форма, прогнозно количество 16 000 mg.

ID

ocds-pyfy63:2020-255944:obj:17

Classification

CPV / 33600000

Description

Docetaxel 80 mg., парентерална форма, прогнозно количество 32 000 mg.

ID

ocds-pyfy63:2020-255944:obj:18

Classification

CPV / 33600000

Description

Epirubicin 50 mg., парентерална форма, прогнозно количество 52 500 mg.

ID

ocds-pyfy63:2020-255944:obj:19

Classification

CPV / 33600000

Description

Buprenorphin 35 mcg/h, Transdermal patch, прогнозно количество 14 000 mcg/h

ID

ocds-pyfy63:2020-255944:obj:20

Classification

CPV / 33600000

Description

Buprenorphin 52,5 mcg/h, Transdermal patch, прогнозно количество 15 750 mcg/h

ID

ocds-pyfy63:2020-255944:obj:21

Classification

CPV / 33600000

Description

Buprenorphin 70 mcg/h, Transdermal patch, прогнозно количество 31 500 mcg/h

ID

ocds-pyfy63:2020-255944:obj:22

Classification

CPV / 33600000

Description

Enzalutamide 40 mg., перорална форма, прогнозно количество 1 953 280mg.

ID

ocds-pyfy63:2020-255944:obj:23

Classification

CPV / 33600000

Description

Cisplatin 1mg/ml – 50 ml., парентерална форма, прогнозно количество 20 000 mg.

ID

ocds-pyfy63:2020-255944:obj:24

Classification

CPV / 33600000

Description

Carboplatin 10mg/ml – 15 ml., парентерална форма, прогнозно количество 210 000 mg.

ID

ocds-pyfy63:2020-255944:obj:25

Classification

CPV / 33600000

Description

Oxaliplatin 5mg/ml – 20 ml., парентерална форма, прогнозно количество 100 000mg.

ID

ocds-pyfy63:2020-255944:obj:26

Classification

CPV / 33600000

Description

Trastuzumab 150 mg., парентерална форма, прогнозно количество 120 000 mg.

ID

ocds-pyfy63:2020-255944:obj:27

Classification

CPV / 33600000

Description

Trastuzumab 600mg/5 ml., Парентерална форма за субкутанно приложение, прогнозно количество 60 000 mg.

ID

ocds-pyfy63:2020-255944:obj:28

Classification

CPV / 33600000

Description

Cetuximab 5mg/ml – 20 ml., парентерална форма, прогнозно количество 98 000 mg.

ID

ocds-pyfy63:2020-255944:obj:29

Classification

CPV / 33600000

Description

Bevacizumab 25mg/ml – 16 ml., парентерална форма, прогнозно количество 128 000 mg.

ID

ocds-pyfy63:2020-255944:obj:30

Classification

CPV / 33600000

Description

Bevacizumab 25mg/ml – 4 ml., парентерална форма, прогнозно количество 52 000 mg.

ID

ocds-pyfy63:2020-255944:obj:31

Classification

CPV / 33600000

Description

Panitumumab 20mg/ml – 5ml, парентерална форма, прогнозно количество 80 000 mg.

ID

ocds-pyfy63:2020-255944:obj:32

Classification

CPV / 33600000

Description

Erlotinib 150 mg., перорална форма, прогнозно количество 99 000 mg.

ID

ocds-pyfy63:2020-255944:obj:33

Classification

CPV / 33600000

Description

Erlotinib 100 mg., перорална форма, прогнозно количество 60 000 mg.

ID

ocds-pyfy63:2020-255944:obj:34

Classification

CPV / 33600000

Description

Sunitinib 12,5 mg., перорална форма, прогнозно количество 9 000 mg.

ID

ocds-pyfy63:2020-255944:obj:35

Classification

CPV / 33600000

Description

Sunitinib 25 mg., перорална форма, прогнозно количество 18 000 mg.

ID

ocds-pyfy63:2020-255944:obj:36

Classification

CPV / 33600000

Description

Sunitinib 50 mg., перорална форма, прогнозно количество 105 000 mg.

ID

ocds-pyfy63:2020-255944:obj:37

Classification

CPV / 33600000

Description

Sorafenib 200 mg., перорална форма, прогнозно количество 1 120 000 mg.

ID

ocds-pyfy63:2020-255944:obj:38

Classification

CPV / 33600000

Description

Afatinib 30 mg., перорална форма, прогнозно количество 20 160 mg.

ID

ocds-pyfy63:2020-255944:obj:39

Classification

CPV / 33600000

Description

Afatinib 40 mg., перорална форма, прогнозно количество 26 880 mg.

ID

ocds-pyfy63:2020-255944:obj:40

Classification

CPV / 33600000

Description

Lapatinib 250 mg., перорална форма, прогнозно количество 1 680 000 mg.

ID

ocds-pyfy63:2020-255944:obj:41

Classification

CPV / 33600000

Description

Trastuzumab emtansine 100mg/5 ml., парентерална форма, прогнозно количество 14 400 mg.

ID

ocds-pyfy63:2020-255944:obj:42

Classification

CPV / 33600000

Description

Trastuzumab emtansine 160mg/8 ml., парентерална форма, прогнозно количество 23 040 mg.

ID

ocds-pyfy63:2020-255944:obj:43

Classification

CPV / 33600000

Description

Everolimus 10 mg., перорална форма, прогнозно количество 14 400 mg.

ID

ocds-pyfy63:2020-255944:obj:44

Classification

CPV / 33600000

Description

Vandetanib 100 mg., перорална форма, прогнозно количество 72 000 mg.

ID

ocds-pyfy63:2020-255944:obj:45

Classification

CPV / 33600000

Description

Vandetanib 300 mg., перорална форма, прогнозно количество 432 000 mg.

ID

ocds-pyfy63:2020-255944:obj:46

Classification

CPV / 33600000

Description

Ramucirumab 10mg/ml – 10 ml., парентерална форма, прогнозно количество 17 000 mg

ID

ocds-pyfy63:2020-255944:obj:47

Classification

CPV / 33600000

Description

Pazopanib 400 mg., перорална форма, прогнозно количество 624 000mg.

ID

ocds-pyfy63:2020-255944:obj:48

Classification

CPV / 33600000

Description

Pethidine 50mg/ml – 2 ml., парентерална форма, прогнозно количество 400 000mg.

ID

ocds-pyfy63:2020-255944:obj:49

Classification

CPV / 33600000

Description

Pertuzumab 420 mg., парентерална форма, прогнозно количество 57 120 mg.

ID

ocds-pyfy63:2020-255944:obj:50

Classification

CPV / 33600000

Description

Aflibercept 25mg/ml – 4 ml., парентерална форма, прогнозно количество 4 800 mg.

ID

ocds-pyfy63:2020-255944:obj:51

Classification

CPV / 33600000

Description

Aflibercept 25mg/ml – 8 ml., парентерална форма, прогнозно количество 19 200 mg.

ID

ocds-pyfy63:2020-255944:obj:52

Classification

CPV / 33600000

Description

Lipegfilgrastim 6mg/0,6 ml., парентерална форма, прогнозно количество 576 mg.

ID

ocds-pyfy63:2020-255944:obj:53

Classification

CPV / 33600000

Description

Epirubicin 2mg/ml – 50 ml., парентерална форма, прогнозно количество 200 000mg.

ID

ocds-pyfy63:2020-255944:obj:54

Classification

CPV / 33600000

Description

Topotecan 4 mg., парентерална форма, прогнозно количество 40 mg.

ID

ocds-pyfy63:2020-255944:obj:55

Classification

CPV / 33600000

Description

Irinotecan 100 mg., парентерална форма, прогнозно количество 36 000 mg.

ID

ocds-pyfy63:2020-255944:obj:56

Classification

CPV / 33600000

Description

Gefitinib 250 mg., перорална форма, прогнозно количество 180 000 mg.

ID

ocds-pyfy63:2020-255944:obj:57

Classification

CPV / 33600000

Description

Cabazitaxel 60 mg., парентерална форма, прогнозно количество 2 880 mg.

ID

ocds-pyfy63:2020-255944:obj:58

Classification

CPV / 33600000

Description

Abiraterone acetate 500 mg., перорална форма, прогнозно количество 12 000 000mg.

ID

ocds-pyfy63:2020-255944:obj:59

Classification

CPV / 33600000

Description

Vemurafenib 240 mg., перорална форма, прогнозно количество 2 499 840 mg.

ID

ocds-pyfy63:2020-255944:obj:60

Classification

CPV / 33600000

Description

Eribulin 0,44mg/ml – 2 ml., парентерална форма, прогнозно количество 322,08mg.

ID

ocds-pyfy63:2020-255944:obj:61

Classification

CPV / 33600000

Description

Filgrastim 30 MU (300 mcg/0.5 ml), парентерална форма, прогнозно количество 360 000 mcg.

ID

ocds-pyfy63:2020-255944:obj:62

Classification

CPV / 33600000

Description

Zoledronic acid 4mg/5 ml., парентерална форма, прогнозно количество 16 000 mg.

ID

ocds-pyfy63:2020-255944:obj:63

Classification

CPV / 33600000

Description

Denosumab 120mg/1,7 ml., парентерална форма, прогнозно количество 144 000 mg.

ID

ocds-pyfy63:2020-255944:obj:64

Classification

CPV / 33600000

Description

Olaparib 50 mg., перорална форма, прогнозно количество 201 600mg.

ID

ocds-pyfy63:2020-255944:obj:65

Classification

CPV / 33600000

Description

Doxorubicin hydrochl. 50 mg., парентерална форма, прогнозно количество 4 800mg.

ID

ocds-pyfy63:2020-255944:obj:66

Classification

CPV / 33600000

Description

Crizotinib 250 mg., перорална форма, прогнозно количество 720 000 mg.

ID

ocds-pyfy63:2020-255944:obj:67

Classification

CPV / 33600000

Description

Axitinib 1 mg., перорална форма, прогнозно количество 2 688 mg.

ID

ocds-pyfy63:2020-255944:obj:68

Classification

CPV / 33600000

Description

Axitinib 5 mg., перорална форма, прогнозно количество 13 340 mg.

ID

ocds-pyfy63:2020-255944:obj:69

Classification

CPV / 33600000

Description

Nivolumab 10 mg/ml - 4 ml, парентерална форма, прогнозно количество 3 840 mg.

ID

ocds-pyfy63:2020-255944:obj:70

Classification

CPV / 33600000

Description

Nivolumab 10 mg/ml - 10 ml, парентерална форма, прогнозно количество 19 200 mg.

ID

ocds-pyfy63:2020-255944:obj:71

Classification

CPV / 33600000

Description

Trifluridine/Tipiracil 15 mg/6.14 mg, перорална форма, прогнозно количество 480 tabl.

ID

ocds-pyfy63:2020-255944:obj:72

Classification

CPV / 33600000

Description

Trifluridine/Tipiracil 20 mg/8,19 mg, перорална форма, прогнозно количество 960 tabl.

ID

ocds-pyfy63:2020-255944:obj:73

Classification

CPV / 33600000

Description

Morphine 20mg/ml – 1 ml., парентерална форма, прогнозно количество 40 000 mg.

ID

ocds-pyfy63:2020-255944:obj:74

Classification

CPV / 33600000

Description

Oxycodone 10 mg., перорална форма, прогнозно количество 200 000 mg.

ID

ocds-pyfy63:2020-255944:obj:75

Classification

CPV / 33600000

Description

Oxycodone 20 mg., перорална форма, прогнозно количество 960 000 mg.

ID

ocds-pyfy63:2020-255944:obj:76

Classification

CPV / 33600000

Description

Oxycodone 40 mg., перорална форма, прогнозно количество 800 000 mg.

ID

ocds-pyfy63:2020-255944:obj:77

Classification

CPV / 33600000

Description

Fentanyl 50mcg/h, трансдермален пластир, прогнозно количество 120 000 mcg/h.

ID

ocds-pyfy63:2020-255944:obj:78

Classification

CPV / 33600000

Description

Fentanyl 100mcg/h, трансдермален пластир, прогнозно количество 240 000 mcg/h.

ID

ocds-pyfy63:2020-255944:obj:79

Classification

CPV / 33600000

Description

Tramadol 50 mg., перорална форма, прогнозно количество 886 000 mg.

ID

ocds-pyfy63:2020-255944:obj:80

Classification

CPV / 33600000

Description

Dihydrocodeine 90 mg., перорална форма, прогнозно количество 324 000mg.

ID

ocds-pyfy63:2020-255944:obj:81

Classification

CPV / 33600000

Description

Calcium folinate 10 mg/ml – 5 ml, парентерална форма, прогнозно количество 300 000 mg.

ID

ocds-pyfy63:2020-255944:obj:82

Classification

CPV / 33600000

Description

Tramadol 50mg/ml - 2 ml., парентерална форма, прогнозно количество 1 500 амп.

ID

ocds-pyfy63:2020-255944:obj:83

Classification

CPV / 33600000

Description

Dexamethasone 4 mg./1 ml.,парентерална форма, прогнозно количество 2 000 амп.

ID

ocds-pyfy63:2020-255944:obj:84

Classification

CPV / 33600000

Description

Alectinib 150 mg., перорална форма, прогнозно количество 806 400 mg.

ID

ocds-pyfy63:2020-255944:obj:85

Classification

CPV / 33600000

Description

Crizotinib 250 mg., перорална форма, прогнозно количество 360 000 mg.

ID

ocds-pyfy63:2020-255944:award:0

Title

Mycobacterium bovis BCG (Baccilus Calmette — Guerin)

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:1

Title

Erythropoietin (Epoetin alfa) 10 000 IU/1ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:2

Title

Darbepoetin alfa 300 mcg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:3

Title

Octreotide 30 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:4

Title

Octreotide 20 mg

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:5

Title

Cyclophosphamide 500 mg

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:6

Title

Temozolomide 100 mg., Capsule, hard

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:7

Title

Pemetrexed 25 mg/ml - 20 ml

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:8

Title

Fluorouracil 50mg/ml – 20 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:9

Title

Gemcitabine 1000 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:10

Title

Capecitabine 500 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:11

Title

Vinorelbine 10 mg/ml - 5 ml

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:12

Title

Etoposide 20 mg/ml- 5 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:13

Title

Paclitaxel 100 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:14

Title

Paclitaxel 300 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:15

Title

Docetaxel 160 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:16

Title

Docetaxel 80 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:17

Title

Epirubicin 50 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:18

Title

Buprenorphin 35 mcg/h

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:19

Title

Buprenorphin 52,5 mcg/h

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:20

Title

Buprenorphin 70 mcg/h

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:21

Title

Enzalutamide 40 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:22

Title

Cisplatin 1mg/ml – 50 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:23

Title

Carboplatin 10mg/ml – 15 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:24

Title

Oxaliplatin 5mg/ml – 20 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:25

Title

Trastuzumab 150 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:26

Title

Trastuzumab 600mg/5 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:27

Title

Cetuximab 5mg/ml – 20 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:28

Title

Bevacizumab 25mg/ml – 16 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:29

Title

Bevacizumab 25mg/ml – 4 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:30

Title

Panitumumab 20mg/ml – 5ml

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:31

Title

Erlotinib 150 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:32

Title

Erlotinib 100 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:33

Title

Sunitinib 12,5 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:34

Title

Sunitinib 25 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:35

Title

Sunitinib 50 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:36

Title

Sorafenib 200 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:37

Title

Afatinib 30 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:38

Title

Afatinib 40 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:39

Title

Lapatinib 250 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:40

Title

Trastuzumab emtansine 100mg/5 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:41

Title

Trastuzumab emtansine 160mg/8 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:42

Title

Everolimus 10 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:43

Title

Vandetanib 100 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:44

Title

Vandetanib 300 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:45

Title

Ramucirumab 10mg/ml – 10 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:46

Title

Pazopanib 400 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:47

Title

Pethidine 50mg/ml – 2 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:48

Title

Pertuzumab 420 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:49

Title

Aflibercept 25mg/ml – 4 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:50

Title

Aflibercept 25mg/ml – 8 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:51

Title

Lipegfilgrastim 6mg/0,6 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:52

Title

Epirubicin 2mg/ml – 50 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:53

Title

Topotecan 4 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:54

Title

Irinotecan 100 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:55

Title

Gefitinib 250 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:56

Title

Cabazitaxel 60 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:57

Title

Abiraterone acetate 500 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:58

Title

Vemurafenib 240 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:59

Title

Eribulin 0,44mg/ml – 2 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:60

Title

Filgrastim 30 MU (300 mcg/0.5 ml)

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:61

Title

Zoledronic acid 4mg/5 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:62

Title

Denosumab 120mg/1,7 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:63

Title

Olaparib 50 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:64

Title

Doxorubicin hydrochl. 50 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:65

Title

Crizotinib 250 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:66

Title

Axitinib 1 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:67

Title

Axitinib 5 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:68

Title

Nivolumab 10 mg/ml - 4 ml

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:69

Title

Nivolumab 10 mg/ml - 10 ml

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:70

Title

Trifluridine/Tipiracil 15 mg/6.14 mg

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:71

Title

Trifluridine/Tipiracil 20 mg/8,19 mg

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:72

Title

Morphine 20mg/ml – 1 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:73

Title

Oxycodone 10 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:74

Title

Oxycodone 20 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:75

Title

Oxycodone 40 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:76

Title

Fentanyl 50mcg/h

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:77

Title

Fentanyl 100mcg/h

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:78

Title

Tramadol 50 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:79

Title

Dihydrocodeine 90 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:80

Title

Calcium folinate 10 mg/ml – 5 ml

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:81

Title

Tramadol 50mg/ml - 2 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:82

Title

Dexamethasone 4 mg./1 ml.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:83

Title

Alectinib 150 mg.

Status

cancelled

ID

ocds-pyfy63:2020-255944:award:84

Title

Crizotinib 250 mg.

Status

cancelled

Roles

buyer

Organization name

„Spetsializirana bolnitsa za aktivno lechenie na onkologichni zabolyavaniya — Sofiya-oblast“ EOOD

Street address

bul. „Stoletov“ No. 67

Locality

Sofiya

Postal code

1233

Country

BG

Contact name

Vasilka Arangelova

E-mail

sbaloz@sbaloz-sofobl.com

Phone

+359 28013948

Fax

+359 28321156

Website

Link

Organization data Organization in JSON